Document is current
Any future updates will be listed below
-
Authors
Maruhashi, Takumi https://orcid.org/0000-0003-2944-1611
Sugiura, Daisuke https://orcid.org/0000-0002-3865-3889
Okazaki, Il-mi https://orcid.org/0000-0001-8644-0100
Okazaki, Taku https://orcid.org/0000-0003-4790-1925
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02460224 at ClinicalTrials.govDocuments that mention this clinical trial
Gene of the month: lymphocyte-activation gene 3 (LAG-3)
https://doi.org/10.1136/jclinpath-2021-207517
Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives
https://doi.org/10.1016/j.ejca.2016.02.020
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
https://doi.org/10.1136/jitc-2021-003776
387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies
https://doi.org/10.1136/jitc-2020-sitc2020.0387
Optimizing anti-PI3Kδ and anti-LAG-3 immunotherapy dosing regimens in a mouse model of triple-negative breast cancer improves outcome by removing treatment-related adverse events
https://doi.org/10.1136/jitc-2025-012157
LAG-3: from molecular functions to clinical applications
https://doi.org/10.1136/jitc-2020-001014
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP18H05417)
Japan Society for the Promotion of Science (JP18K19453)
Japan Society for the Promotion of Science (JP19H01029)
Japan Society for the Promotion of Science (JP19H03423)
Japan Society for the Promotion of Science (JP19K16694)
- License Information
